We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-4.45%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.08B
AUM Growth
+$322M
Cap. Flow
+$648M
Cap. Flow %
21%
Top 10 Hldgs %
37.4%
Holding
321
New
89
Increased
78
Reduced
45
Closed
96

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32M
2
CCCC icon
C4 Therapeutics
CCCC
+$14.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.1M
4
AMRS
Amyris Inc.
AMRS
+$11M
5
TECH icon
Bio-Techne
TECH
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.1M
2
DXCM icon
DexCom
DXCM
+$14.1M
3
ICUI icon
ICU Medical
ICUI
+$14M
4
LIVN icon
LivaNova
LIVN
+$12.2M
5
OLPX
Olaplex Holdings
OLPX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 24.06%
2 Materials 0.35%
3 Industrials 0.17%
4 Consumer Discretionary 0.07%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
276
Roivant Sciences
ROIV
$26.1B
– –
-104,413
Closed -$1.05M
RPID icon
277
Rapid Micro Biosystems
RPID
$84.8M
– –
-276,871
Closed -$2.95M
RVTY icon
278
PUT
Revvity
RVTY
$13.2B
– –
-69,600
Closed -$14M
SKIN icon
279
SkinHealth Systems
SKIN
$84.2M
– –
-596,981
Closed -$9.85M
TFX icon
280
PUT
Teleflex
TFX
$6.03B
– –
-25,800
Closed -$8.47M
VIR icon
281
Vir Biotechnology
VIR
$1.52B
– –
-21,685
Closed -$908K
VRTX icon
282
CALL
Vertex Pharmaceuticals
VRTX
$133B
– –
-97,000
Closed -$21.3M
XLV icon
283
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$44B
– –
-400,000
Closed -$56.4M
SNAX
284
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
– –
-29,170
Closed -$1.73M
PSTX
285
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-89,886
Closed -$612K
AXNX
286
PUT
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-59,100
Closed -$3.31M
TBIO
287
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
– –
-31,794
Closed -$6.18M
ARYD
288
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-510,507
Closed -$5.06M
OMIC
289
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-3,018
Closed -$1.05M
DCPH
290
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-98,200
Closed -$959K
DCPH
291
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-114,945
Closed -$1.12M
DCPH
292
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-65,700
Closed -$642K
NGM
293
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-42,069
Closed -$745K
NSTG
294
CALL
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-118,600
Closed -$5.01M
IMGN
295
CALL
DELISTED
Immunogen Inc
IMGN
– –
-325,000
Closed -$2.41M
IMGN
296
DELISTED
Immunogen Inc
IMGN
– –
-249,283
Closed -$1.85M
IMGN
297
PUT
DELISTED
Immunogen Inc
IMGN
– –
-484,600
Closed -$3.6M
MRTX
298
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-4,872
Closed -$715K
NUVA
299
PUT
DELISTED
NuVasive, Inc.
NUVA
– –
-216,900
Closed -$11.4M
AMRS
300
CALL
DELISTED
Amyris Inc.
AMRS
– –
-2,200,000
Closed -$11.9M
9 10 11
12
13

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Pura Vida Investments held 321 positions worth $3.08B, up 12% from $2.76B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $648M of net new capital in Q1 2022, opening 89 new positions and adding to 78 existing holdings. Its largest new stake was Biogen: 147,135 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 30% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was ICU Medical, an estimated $14M trimmed.

  • Pura Vida Investments's largest Q1 2022 buy was Biogen: 147,135 shares worth $31M.
  • Pura Vida Investments added most to C4 Therapeutics in Q1 2022, an estimated $14.5M increase.
  • Pura Vida Investments's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $14M.
  • Pura Vida Investments fully exited Natera in Q1 2022, selling an estimated $14.1M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $3.08B portfolio in Q1 2022.
  • Pura Vida Investments opened 89 new positions and closed 96 in Q1 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $3.08B.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.